Second ZMapp-Treated Patient Dies of Ebola, Supplies Run Out
August 25, 2014 7:03 PM
Amid efficacy questions, a Japanese antiviral drug is also being evaluated to combat the deadly disease
The World Health Organization
(WHO), the health department of
the United Nations
(UN), revealed on Friday that
that's gripped central Africa has now claimed over 1,400 lives. Adding to the bad news, supplies of the experimental drug ZMapp have reportedly been exhausted and a recent death of a ZMapp-treated doctor is increasing questions of the drug's efficacy, as health workers in Africa desperately search for a way to treat -- or at least stop the spread of -- the deadly virus.
I. ZMapp -- an Exotic Treatment Option
is a monoclonal antibody produced in plants, and then humanized. Antibodies are large Y-shapped proteins that the human body uses to tag "antigens" surface chemicals on hostile invaders such as viruses and bacteria. More specifically, in this case the antibodies are thought to tag strains of the Ebola family of viruses (EBOVs), including the most prevalent and deadly titular strain, the
The Ebola virus is cutting a wake of destruction across Central Africa. [Image Source: AP]
The ZMapp effort was formed by the merger of two attempts to produce monoclonal antibody serums via genetically modified organism (GMOs). The first serum was MB-003, formulated by San Diego, Calif.-based Mapp Biopharmaceutical, Inc. and its commerical sister-firm LeafBio. Both Mapp and Leafbio were
[PDF] in part by grants from the
U.S. Army Medical Research Institute of Infectious Diseases
(USAMRID). The second serum was ZMAb, made by Toronto-based
, a startup funded in part by grants from a Public Health Agency of Canada (PHAC) grant.
Both Defyrus and Mapp/LeafBio are tiny, very young firms; Defyrus was found in 2008, Mapp in 2003. Defyrus has six employees, Mapp has nine. Both companies look to use purified antibodies from GMOs to try to boost a patients' defense against disease which currently have no cure. Because of this, both companies fall under the so-called "biodefense" category as they could provide a novel tool to combat rare deadly diseases -- a highly coveted weaponizable class of pathogens.
The ZMapp cocktail is produced by infecting
, a close relative of cigarette tobacco, with a virus similar to the target viral agent. The tobacco plants are grown at the U.S. and Canadian companies' German partner firm, Icon Genetics. Leaves are grown in small batches at Icon Genetic's greenhouse. Genes are introduced into the plants via recombinant bacteria administered by eyedroppers.
Leaves are picked at a Icon Genetics greenhouse in Germany and readied for extraction.
[Image Source: Reuters]
The crop responds to the infection by producing antibodies. After the harvest, workers much grind the leaves and carry out a set of hand extractions and purifications.
Via this costly, slow process a batch of serum is made. The antibodies are "
" either using recombinant DNA in the plant or via scaffold or rodent reporcessing -- processes that make these immune proteins compatible with the human body, despite coming from a highly different source organism.
Defyrus and Mapp/LeafBio must painstakingly extract and mix the proteins for each batch of ZMapp by hand.
[Image Source: Reuters]
Humanized monoclonal antibodies are being considered for novel forms of cancer treatment, as well as for combatting rare and understudied diseases. The fundamental idea in both cases is to get nature to do medical researchers' dirty work at a much faster speed. The downside is that these treatments get very expensive as the process is very new. Purification and humanification technologies are far from achieving the levels needed to achieve the production associated with common antibiotics and vaccines. And many of the formulations -- including ZMapp -- have not gone through clinical trials, and at this point can be considered at best educated guesses.
II. Great Expectations
At first it perhaps appeared to the overly hopeful observer that ZMapp might be a magic bullet for the EBOV. After Mapp and Defyrus received a rare exemption from the U.S. Food and Drug Administration (FDA) allowing experimental treatment of patients with a drug that has yet to undergo clinical trials, the ZMapp formula was used to treat two Americans.
The lucky potentially lucky recipients of the expensive experimental cocktail were Kent Brantly, a 33-year-old doctor, and Nancy Writebol, a 59-year-old aid worker. Both the patients became infected while trying to assist in combating the current EBOV outbreak in Central Africa.
Both American patients treated with ZMapp recovered fully. [Image Source: Bloomberg]
near Atlanta, Georgia, both patients made remarkable recoveries. Closely monitored by teams of doctors and provided an ample supply of sterile fluids to keep them hydrated, both of these ZMapp-treated patients
made full recoveries
. Recently, after a quarantine they were
allowed to go home
to family members in the U.S. after being deemed no longer contagious. Dr. Brantly cheered that his recovery with the help of ZMapp was "miraculous."
Cheered by the results, further purchases of ZMapp were made to treat an infected Spanish missionary and African doctors. The serum was also given to
three African doctors treating patients in Liberia who had become infected with EBOV. After receiving doses of ZMapp all three doctors subsequently showed
signs of a "remarkable" recovery
, according to local officials.
But the optimism was dampered somewhat when Rev. Miguel Pajares, a 75-year-old missionary, died despite receiving treatment with ZMapp. Rev. Pajares was treated at the state of the art Carlos III Hospital in Madrid, Spain, but neither the cutting edge medical center nor the ZMapp was able to save his life.
More bad news arrived this week when Liberia's Dr. Abraham Borbor -- one of the African doctors who received ZMapp -- took a turn for the worse and died, after appearing poised to make a full recovery. News of the death was
shared to various outlets
by Liberian Information Minister Lewis Brown. The loss of Dr. Borbor was a major blow as he was the Deputy Chief Medical Doctor of the leading medical institution in hardest hit African nation, Liberia. Dr. Borbor's age was not widely reported, but he appears to be middle-aged.
Dr. Abraham Borbor, a top medical doctor in Liberia, died this week, despite being one of only three Africans to receive treatment with the expensive drug ZMapp. [Image Source: Dailly Mail]
The latest development calls into question to some extent the efficacy of ZMapp, as thus far 2 patients treated with it have died, while two have made full recoveries. Further complicating the issue is that supplies of ZMapp have run out, so there can be no more additional tests for now. Mapp/LeafBio and Defyrus are working to prepare more doses, but they may not be ready until a few months from now, given the lengthy grow time need to make small batches of the treatment.
Some will surely point to potential differences the condition and treatment of patients who were given ZMapp and died versus those who lived. Both of the patients who made full recoveries were younger than 65 and were treated at modern medical institutions. Of those who died, the Liberian doctor was treated at a top regional facility, but without some of the advanced amenities of a European or Amerian hospital. The Spanish priest's age, meanwhile, is being attributed as a factor in that case for the lack of success.
III. Now It's Toyama's Turn
Greater mortality rates for the infection are estimated to be around 55 percent,
. And that brings to bear the elephant in the room. Other factors aside, the survival rate for ZMapp treated patients isn't significantly higher.
The scant supply of ZMapp has been exhausted without conclusive results. [Image Source: Getty Images]
At the end of the day, though, we're back to where we started. ZMapp may indeed be useful in combatting the disease, but it remains highly expensive and slow to produce. Worse, critics and proponents at best have
educated speculation and anecdotal cases
studies to rely upon when trying to determine its efficacy. ZMapp may "work" to some extent; or it may have little impact on the course of the disease versus other factors. At this point there simply isn't enough evidence to determine which is the case.
But if ZMapp can't stop Ebola, what can? The answer may lie in other experimental drugs, such as T-705, an antiviral drug marketed under the name Avigan. This new antiviral is produced by Japan's Toyama Chemical Comp., Ltd., which recently became a subsidiary of Fujifilm Holdings Corp. (
). Avigan has been through limited clinical trials with other viruses. It is currently approved of to treat influenza in Japan.
Avigan, an inhibitor of viral RNA polymerases, is being tried as an alternative to ZMapp.
[Image Source: Fujifilm]
No one knows if it will be able to similarly slow EBOVs, but Japan has already cleared red tape to allow it to ship worldwide -- with or without WHO approval. Avigan is currently being tested on William Pooley, a 29-year-old British volunteer, who returned home after contracting EBOV as a relief worker. He's being treated in isolation at a London, UK hospital.
Should Avigan pan out, the big upside is that unlike ZMapp, it could potentially be produced at much higher volume and far more quickly. Indeed, Fujifilm and Toyama Chemical sound eager to do so. But care must be taken as thus far other less exotic antivirals have had little success at combatting EBOV. The worst case scenario would be for afflicted nations to purchase large stocks of the antiviral, only to find in an inaffective treatment.
Meanwhile the disease marches on, unchecked in the worst-hit nations of Liberia and Sierra Leone.
The latest statistics
from the WHO lists 2,615 infections and 1,427 deaths for the latest outbreak -- a infection count higher than the past 20 EBOV outbreaks combined.
The death toll from the epidemic has topped 1,400. [Image Source: CDC]
The good news is that Nigeria -- Africa's most populous nation -- has thus far managed to constrain EBOV disease occurences to a dozen or so cases. Of the five deaths in Nigeria, all have been related to those who came in contact with an American-born citizen of Liberia who traveled to Nigeria after becoming infected with EBOV in his home country.
But in Liberia, particularly, the situation remains grim.
"It seems as though my state-funded math degree has failed me. Let the lashings commence." -- DailyTech Editor-in-Chief Kristopher Kubicki
Second Ebola Patient Lands on U.S. Soil, CDC Preps 20 U.S. Quarantine Camps
August 5, 2014, 2:21 PM
PIQ ROBOTTM reveals its new artificial intelligence software
November 29, 2016, 12:59 AM
One more time - Happy Thanksgiving to Everyone Around the World
November 24, 2016, 4:00 AM
Google’s Smart Contact Lens Project gets halted for 2016
November 20, 2016, 7:00 AM
Cell Research Study shows African Americans have greater immune response to infection
November 10, 2016, 1:00 AM
UTHealth Clinical Trial Shows Progress Using Stem Cells to Treat Traumatic Brain Injury
November 8, 2016, 1:00 AM
Uber Partners with Circulation to Pilot Program Connecting Transportation and Digital Health Care
November 6, 2016, 5:00 AM
Most Popular Articles
Kobo Aura One Vs Kindle Paperwhite
January 10, 2017, 1:21 AM
New at CES 2017 - Changhong 8K Super Slim TV 65ZHQ3R
January 8, 2017, 1:07 AM
OPPO R9 – The Smartphone with Excellent Camera and Long Battery Life
January 12, 2017, 12:01 AM
Are you in the market for a private antenna?
January 11, 2017, 12:01 AM
Comparison: Xiaomi Mi Mix Vs. HTC U Ultra
January 14, 2017, 12:10 AM
Latest Blog Posts
News of the Day
Jan 16, 2017, 12:10 PM
News and Technology Advancement
Jan 16, 2017, 7:58 AM
Jan 15, 2017, 12:32 AM
Here is Some News
Jan 14, 2017, 12:39 AM
News: Improved and New products
Jan 13, 2017, 12:01 AM
News around the world
Jan 12, 2017, 12:01 AM
Rumors and Announcements
Jan 11, 2017, 12:01 AM
This year CES and ridiculous gadgets
Jan 10, 2017, 12:01 AM
Nokia Android phone spurns the west.
Jan 9, 2017, 12:08 AM
New at CES 2017 - Changhong 8K Super Slim TV 65ZHQ3R
Jan 8, 2017, 1:07 AM
Debuted at CES 2017 - Vuzix Blade 3000 Smart Sunglasses
Jan 8, 2017, 12:39 AM
Some news of Day
Jan 7, 2017, 12:01 AM
News 2017 CES
Jan 6, 2017, 12:01 AM
Here is the Latest News in Tech
Jan 5, 2017, 1:47 AM
AI Beats World’s Best at Chinese board game “Go”
Jan 4, 2017, 11:21 AM
Las Vegas 2017 CES
Jan 3, 2017, 12:01 AM
News of Jan 2nd 2017
Jan 2, 2017, 4:40 AM
Wishing you all, the New Year brings the light of hope, joy, success, and Happy, Happy New Year.
Jan 1, 2017, 1:48 AM
More Blog Posts
Copyright 2017 DailyTech LLC. -
Terms, Conditions & Privacy Information